TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

被引：0
|
作者：
Mariette, X. [1 ]
Curtis, J. [2 ]
Lee, E. [3 ]
Benda, B. [4 ]
Kaplan, I. [5 ]
Soma, K. [5 ]
Kwok, K. [6 ]
Geier, J. [6 ]
Wang, L. [5 ]
Riese, R. [5 ]
机构：
[1] Univ Paris Sud, Hop Bicetre, Paris, France
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Collegeville, PA USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2139
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0147
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [41] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: CHANGES IN LYMPHOCYTES AND LYMPHOCYTE SUBSET COUNTS AND REVERSIBILITY AFTER UP TO 8 YEARS OF TOFACITINIB TREATMENT
    van Vollenhoven, R.
    Choy, E.
    Lee, E. B.
    Hazra, A.
    Anisfeld, A.
    Lazariciu, I.
    Biswas, P.
    Lamba, M.
    Menon, S.
    Hodge, J.
    Clark, J. D.
    Wang, L.
    Krishnaswami, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 258 - 258
  • [42] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN A RHEUMATOID ARTHRITIS OPEN-LABEL EXTENSION STUDY FOLLOWING ADALIMUMAB THERAPY IN A PHASE 3 RANDOMISED CLINICAL TRIAL
    Genovese, M.
    van Vollenhoven, R.
    Wilkinson, B.
    Wang, L.
    Zwillich, S.
    Gruben, D.
    Benda, B.
    Jones, T.
    Bradley, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 65
  • [43] Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
    Genovese, M. C.
    van Vollenhoven, R. F.
    Wilkinson, B.
    Wang, L.
    Zwillich, S. H.
    Gruben, D.
    Benda, B.
    Jones, T. V.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S190 - S191
  • [44] A comparison of Janus kinase inhibitor safety in rheumatoid arthritis
    Nash, Peter
    Lim, Irwin
    Marabani, Mona
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 : 3 - 14
  • [45] Janus-Kinase-Inhibitor Baricitinib in rheumatoid Arthritis
    Alten, R.
    Nitschmann, S.
    INTERNIST, 2017, 58 (12): : 1341 - 1344
  • [46] The Janus-Kinase-Inhibitor Tofacitinib
    Krome, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (01): : 7 - 7
  • [47] Baricitinib and Tofacitinib in Real Life - Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
    Meissner, Yvette
    Baganz, Lisa
    Schneider, Matthias
    Schwarze, Ilka
    Feuchtenberger, Martin
    Zink, Angela
    Strangfeld, Anja
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] Case History: Xeljanz™ (Tofacitinib Citrate), a First-in-Class Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis
    Flanagan, Mark E.
    Brown, Matthew F.
    Subramanyam, Chakrapani
    Munchhof, Michael J.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 399 - 416
  • [49] Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
    Burgos-Vargas, Ruben
    Cardiel, Mario
    Xibille, Daniel
    Pacheco-Tena, Cesar
    Pascual-Ramos, Virginia
    Abud-Mendoza, Carlos
    Mahgoub, Ehab
    Rahman, Mahboob
    Fan, Haiyun
    Rojo, Ricardo
    Garcia, Erika
    Santana, Karina
    REUMATOLOGIA CLINICA, 2019, 15 (01): : 43 - 53
  • [50] Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis
    Palasik, Brittany N.
    Wang, Hongmei
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (06) : 913 - 921
12345